Delivery Order SPE2DR25D1053-SPE2DR26FV302
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $42,932.71 by the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract is scheduled for completion by August 20, 2025, and will be fulfilled at the company's Conshohocken facility. The award represents a child order under AmerisourceBergen's...
- On January 7, 2026, the Defense Logistics Agency awarded a $40,985.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors. This non-set-aside contract is a child order under AmerisourceBergen's significant Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 2026. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,955.33 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors. This competitive award, issued on December 11, 2025, with an ultimate completion date of December 12, 2025, represents a firm fixed-price transaction with no set-aside designation. The drug will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a $77,269.39 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of October 16, 2025. This non-set-aside, firm fixed-price contract represents a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was made competitively and reflects...
- The Defense Logistics Agency awarded a delivery order valued at $6,498.56 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed-price, competitively awarded contract was executed on January 2, 2026, with an ultimate completion date of January 5, 2026. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. REPATHA is a prescription medication used to treat high cholesterol, and the SureClick delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,081.08 by the Defense Logistics Agency (DLA) on September 2, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. The contract employs firm fixed price pricing and carries an ultimate completion date of September 3, 2025, with performance to be executed at the contractor's Conshohocken, PA facility. This delivery order represents...
- The Defense Logistics Agency awarded a $41,759.43 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is the vendor's...
- The Defense Logistics Agency awarded a $11,283.59 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick autoinjectors on September 18, 2025, with an ultimate completion date of September 19, 2025. This firm fixed price, competitively awarded contract (no set-aside used) is for delivery to the company's headquarters in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $18,426.38 delivery order to AmerisourceBergen Drug Corp on December 5, 2025, for REPATHA 140 MG/ML SureClick auto-injector pharmaceutical products, with final delivery due by December 8, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The contract involves...
- The Defense Logistics Agency awarded a $6,289.44 delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for REPATHA 140 mg/ml SureClick auto-injectors. This is a firm fixed-price, competitively awarded delivery order with a completion date of September 26, 2025. The contract is performed at the contractor's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its primary operations as a major pharmaceutical distributor serving federal...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FV302Delivery Order
Amerisourcebergen Drug Corp (subsidiary of parent company Cencora, Inc.) was awarded a $16,824.46 delivery order by the Defense Logistics Agency on January 7, 2026, for REPATHA 140 MG/ML SureClick autoinjector medication. The contract is a firm fixed-price arrangement with no set-aside designation, indicating competitive award, and is scheduled for completion by January 8, 2026. The place of performance is located in Conshohocken, Pennsylvania, where Amerisourcebergen Drug Corp maintains its corporate headquarters. This delivery order is executed under Amerisourcebergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive pharmaceutical supply contract enables the company to deliver a broad range of medications and medical supplies—including specialty drugs, generic pharmaceuticals, vaccines, and medical devices—to support military healthcare programs globally. REPATHA is a PCSK9 inhibitor used for cholesterol management in patients at high risk for cardiovascular disease, reflecting the company's critical role in supplying specialized pharmaceutical products to the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.8k | 1/6/26 |